Board summary
Key figures
80,554
Registered population
72.3% aged 18–64
12.8%
Aged 65+
ICB 21.9% · England 17.9%
15.2%
Ethnic minority (non-White)
5.0% Asian · England 9.6%
3.5%
In IMD quintile 1
ICB 9.2% · England 21.0%
~2,319
Core20 residents (est.)
Resident basis; registered basis ~2,678 · see page 3
7,455
Hypertension register
+5.70% in 3 yrs · England +5.60%
1,333
SMI register
28.8% of Brighton and Hove (LAD)'s
998
COPD register
Reviews +10.32% in 3 yrs
Forecast to 2030
8,575
Hypertension patients, 2030
+1,120 on today
66.2%
QRISK ≥20% on statins, 2030
+4.47pp over 3 yrs
4.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Deprivation and access shortfalls at Wellbn Healthcare.
Wellbn Healthcare has 8.6% Core20 share, 15.6% QOF vaccination achievement and 36.8% phone access, whereas Charter Medical Centre records 71.0% phone access.
Pre-school booster drop-off and review gaps.
Age-five MMR coverage drops 9.6 pp from dose 1 (93.4%) to dose 2 (83.8%), and asthma reviews reach 60.5% (England 65.7%).
Three-year gains in blood pressure and reviews.
Under-80 blood pressure control rose +12.0% (England +3.2%), mental health blood pressure checks rose +10.8 pp (England +4.4 pp), and COPD reviews rose +10.3%.
Population, age and ethnicity
A working-age population of 72.3% may shape demand alongside 1,261 catchment care beds
Goldstone PCN serves 80,554 registered patients across three practices. Working-age adults aged 18-64 comprise 72.3% of the list (58,280 patients), above Brighton and Hove (71.4%), NHS Sussex ICB (60.5%) and England (62.7%). Older adults aged 65+ account for 12.8% (10,301 patients), below Brighton and Hove (14.0%), NHS Sussex ICB (21.9%) and England (17.9%). Census usual residents in associated areas are 84.8% White (Brighton and Hove 85.4%, NHS Sussex ICB 91.0%, England 81.1%) and 15.2% non-White ethnic minorities, though area Census demographics differ from registered lists. Younger demographics may temper crude chronic disease prevalence, though unverified locally.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Brighton and Hove (LAD) local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Brighton and Hove LA) | 2,702 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 77.9% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 55.1% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Brighton and Hove LA) | 1,485 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Brighton and Hove LA) | 19.9 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 3.5% overall but reaches 8.6% at Wellbn Healthcare
Goldstone PCN has a Core20 cohort of 3.5%, below Brighton and Hove (17.6%), NHS Sussex ICB (9.2%) and England (21.0%), with average IMD decile 6.0. Core20 patients concentrate at Wellbn Healthcare (8.6%, estimated 2,032 patients), versus 1.2% (estimated 303 patients) at Trinity Medical Centre and 1.1% (estimated 343 patients) at Charter Medical Centre. Practice Core20 estimates sum to 2,678, while resident estimates total 2,319. Severe mental illness prevalence is 1.6% (1,333 patients), representing 28.8% of the borough register. Outreach should prioritise the practice with concentrated deprivation.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
1,333
SMI register
1.63% recorded prevalence
449
Learning disability register
0.55% recorded prevalence
56
Care homes, 1,261 beds
In the PCN catchment
8.2%
Provide unpaid care
Brighton and Hove (LAD), Census 2021
The severe mental illness register records 1,333 patients (1.6%), above Brighton and Hove (1.4%), NHS Sussex ICB (1.1%) and England (1.0%). The learning disability register covers 449 patients (0.6%, in line with England, Brighton and Hove, and NHS Sussex ICB at 0.6%). The PCN catchment includes 56 care homes with 1,261 beds, though beds do not establish registered care-home residents.
Severe mental illness: physical health checks
SMI prevalence is 1.6% (England 1.0%). Annual blood pressure checks reach 77.0% (England 83.4%), falling to 70.1% at Charter Medical Centre and 68.1% at Trinity Medical Centre. Recorded BMI is 74.5% (England 82.1%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,455
Hypertension register
+5.70%
Register growth, 3 yrs
Brighton and Hove (LAD) +7.27% · England +5.60%
+6.96pp
BP control, under 80
≤140/90 · +4.90pp aged 80+
+1,120
More patients by 2030
Forecast 8,575 (10.20%)
Hypertension case-finding and control
Recorded hypertension prevalence is 9.1%, below Brighton and Hove (10.5%), NHS Sussex Integrated Care Board (16.3%) and England (15.2%), though this crude register may reflect a younger demographic. Over three years, blood pressure control under age 80 rose +7.0 pp (England +2.1 pp) to 65.0%, trailing Brighton and Hove (65.3%), the ICB (66.8%) and England (67.8%), and reaching 59.0% at Trinity Medical Centre. For patients aged 80 and over, control is 75.7% (England 81.2%). Recent blood pressure checks stand at 87.3% (England 90.0%). Persistent shortfalls against comparators in blood pressure control across both age bands mean structured treatment escalation should be prioritised.
Lipids and statins
Among patients with QRISK ≥ 20%, 56.0% receive lipid-lowering therapy, trailing Brighton and Hove (58.9%), NHS Sussex Integrated Care Board (60.0%) and England (63.6%). Statin treatment for diabetes without cardiovascular disease also lags at 65.1% (England 73.2%). Lower therapy coverage across both indicators suggests an opportunity to audit lipid management.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 80,477 | £2.70 | £2.42 | £1.86 | £217,288 |
| Cardiovascular (all), 2025 | 117,728 | £3.60 | £3.32 | £3.33 | £423,821 |
In 2026, the PCN prescribed 80,477 items for lipid-regulating drugs at £2.70 per item, above Brighton and Hove (£2.47), NHS Sussex Integrated Care Board (£2.42) and England (£1.86), spending £67,601 more than at England's unit cost across 80,477 items. Reviewing formulary choices across practices could help identify the drivers of higher unit costs.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+5.64%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+4.30%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 5.9% (England 6.6%) across 4,601 patients, with 60.5% receiving an annual review (England 65.7%), leaving an unreviewed scale of about 1,800 patients. COPD prevalence is 1.2% (England 1.9%) across 998 registered patients; annual review achievement is 67.9% (England 76.4%), despite +10.3% three-year growth (England +2.8%). COPD reviews reach 55.7% at Charter Medical Centre and 77.1% at Wellbn Healthcare. Review shortfalls could reflect recall timing gaps, unverified locally; checking practice recall logs would test it.
Cancer register and children's immunisation
The cancer register records 2,372 patients (2.9% prevalence vs 3.8% in England). In childhood immunisations, 6-in-1 at 12 months reaches 94.6% (England 91.0%), but pre-school coverage drops by age 5: MMR dose 2 is 83.8%, trailing dose 1 (93.4%) by 9.6 pp, and 4-in-1 booster coverage is 76.5%, below the 95.0% target by 18.5 pp. Attrition could reflect recall friction, unverified locally; checking call-recall logs would test it.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
In 2022, 58.5% of cancers with a known stage in NHS Sussex ICB were diagnosed at stage 1 or 2 (England 55.3%), with a distance of -16.5 pp to the national 75.0% ambition. Reaching that ambition would require about 1,360 extra early-stage diagnoses annually, while known-stage completeness was 64.3% (8,209 of 12,766 registered cancers). Early-stage share rose 5 pp from 2013 to 2022. Goldstone PCN records 62.0% cervical screening coverage aged 25-49 (England 66.8%), falling to 53.7% at Wellbn Healthcare. ICB staging reflects the wider system rather than PCN performance, and unrecorded staging limits interpretation. Screening coverage gaps in primary care coincide with a wider health system that requires substantial.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, University Hospitals Sussex NHS Foundation Trust achieved 65.2% on the cancer 62-day referral to treatment standard, below the 85.0% standard by 19.8 pp (East Sussex Healthcare NHS Trust 67.0%, Surrey and Sussex Healthcare NHS Trust 70.0%, NHS Surrey and Sussex Integrated Care Board 71.5%, England 71.2%). On the 28-day faster diagnosis standard, the trust met 74.0%, trailing the 75.0% standard by 1.0 pp (NHS Surrey and Sussex Integrated Care Board 79.3%, England 79.3%). For diagnostics, 12.9% waited 6+ weeks overall, but colonoscopy reached 39.3% (England 30.8%). Provider performance reflects acute capacity, not PCN delivery.
| Pathways within standard (%) | Sussex | East Sussex Healthcare | Surrey and Sussex Healthcare | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.01 | 84.20 | 77.74 | 79.29 | 79.32 |
| 31-day treatment (96%) | 76.79 | 98.19 | 96.20 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 65.20 | 67.04 | 69.97 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Sussex | East Sussex Healthcare | Surrey and Sussex Healthcare | England |
|---|---|---|---|---|
| MRI | 5.62 | 6.48 | 27.53 | 21.40 |
| CT | 8.57 | 0.48 | 18.49 | 9.92 |
| Echocardiography | 0.39 | 21.94 | 43.78 | 28.48 |
| Colonoscopy | 39.35 | 0.74 | 15.11 | 30.83 |
| Gastroscopy | 20.02 | 0.31 | 21.06 | 29.02 |
| All 15 DM01 tests | 12.95 | 5.27 | 28.50 | 23.14 |
| Community services activity | Brighton and Hove residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 23,615 | 309,615 |
| Referrals | 5,590 | 66,930 |
| Patients with a contact | 7,350 | 85,660 |
Community services (residents of Brighton and Hove), Jun 2026 (provisional). In June 2026, Brighton and Hove residents accounted for 23,615 provisional community care contacts and 32,185 care activities, within 309,615 contacts and 316,320 activities across NHS Surrey and Sussex Integrated Care Board. Adults aged 65+ represented 60.7% of borough contacts (14,325 contacts). These experimental figures reflect submitting providers and resident activity rather than unique PCN patients, highlighting strong community service utilisation among older local cohorts.
Practice variation and patient experience
Practice access and vaccination achievement vary widely, lagging most sharply at Wellbn Healthcare
Across 2025/26, QOF clinical achievement was high across all three practices, reaching 100.0% at Wellbn Healthcare, 99.2% at Trinity Medical Centre, and 98.8% at Charter Medical Centre (England 97.1%). However, vaccination and immunisation achievement diverged by 46.6 pp, from 62.2% at Charter Medical Centre to 15.6% at Wellbn Healthcare (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Trinity | 108 | 1.2 | 59.3% | 75.1% | 93.2% |
| Charter | 109 | 1.1 | 71.0% | 77.2% | 89.6% |
| Wellbn Healthcare | 100 | 8.6 | 36.8% | 54.4% | 67.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Heart failure reviews fell 6.1% over three years while England rose +8.7%
Over three years, Goldstone PCN’s widest delivery lag was in heart failure reviews, which fell 6.1% while England rose +8.7% (ICB +4.5%), leaving current coverage at 70.1% (England 78.5%). Dementia register prevalence contracted 3.2% (England +6.0%) and stroke grew +0.2% (England +2.3%). Conversely, under-80 blood pressure control rose +12.0% (England +3.2%), COPD reviews increased +10.3% (England +2.8%), and mental health blood pressure checks rose +10.8 pp (England +4.4 pp). Slower register expansion may reflect younger demographics rather than under-detection, though unverified locally; an age-standardised audit would test it.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Dementia register
Depression register
Stroke register
Diabetes statin (no CVD)
BP control, under 80
COPD reviews
BP check (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Brighton and Hove (LAD) | Asset | PCN | Brighton and Hove (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 56 (1,261 beds) | n/a | Schools (catchment) | 57 | n/a |
| Children's centres | 6 | 14 | Places of worship | 57 | 113 |
| Libraries | 6 | 13 | Homelessness support (VCS) | 0 | no data |
| Primary schools (LA maintained) | 13 | 35 | Primary academies | 3 | 7 |
| Special schools | n/a | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Across 4,601 asthma patients (5.9% prevalence vs 6.6% in England), 60.5% had a 12-month review (England 65.7%, ICB 62.5%, LAD 60.1%), leaving a scale indicator of 1,818 unreviewed patients (about 1,800). For discussion: run structured recall using a single template alongside flexible review slots and inhaler checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Hypertension and lipid therapy escalation
Hypertension treatment to target is 64.0% (England 70.3%; Trinity Medical Centre under-80 control 59.0%), and QRISK >=20% lipid therapy is 56.0% (England 63.6%). Crude prevalence is 9.1% (7,455 patients; England 15.2%), an unadjusted gap of +1,043 to +4,813. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Pre-school immunisation booster catch-up recall
At age 5 (cohort 136, Q1 2025/26), MMR dose 2 is 83.8% vs 93.4% for dose 1 (9.6 pp difference; Charter Medical Centre 11.1 pp), and 4-in-1 booster is 76.5%, below the 95.0% target by 18.5 pp (ICB 85.8%, England 80.9%). Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Age profile register review (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 outreach and triage (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall and escalation audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall catch-up (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and triage workflow review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Hypertension and lipid therapy escalation (p12) | Hypertension register · Hypertension: QOF prevalence · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 3 · Pre-school immunisation booster catch-up recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
